Truist Securities Maintains Buy on Edwards Lifesciences, Lowers Price Target to $76
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter has maintained a 'Buy' rating on Edwards Lifesciences (NYSE:EW) but lowered the price target from $83 to $76.
October 26, 2023 | 6:04 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Edwards Lifesciences' price target has been lowered from $83 to $76 by Truist Securities, though the 'Buy' rating is maintained.
The news is directly about Edwards Lifesciences and is likely to influence investor sentiment. The lowering of the price target might suggest a potential downside, but the maintained 'Buy' rating indicates that the analyst still sees value in the stock. This could lead to mixed reactions in the market, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100